CNS & Neurological Disorders-Drug Targets
ISSN:1871-5273

CNS & Neurological Disorders-Drug Targets

CNS NEUROL DISORD-DR
学科领域:医学
是否预警:不在预警名单内
是否OA:
录用周期:较慢,6-12周
新锐分区:医学3区
年发文量:129
影响因子:3
JCR分区:Q2

基本信息

目的和范围CNS和神经系统疾病-药物靶点旨在涵盖涉及神经和中枢神经系统的当代分子靶点的药物化学、药理学、分子生物学、基因组学和生物化学的所有最新和突出的发展(CNS)疾病例如疾病特异性蛋白质、受体、酶中枢神经系统和神经系统疾病-药物靶点出版客座编辑的主题问题写的领导人在该领域涵盖了一系列当前的主题中枢神经系统和神经系统药物靶点。该杂志还接受发表原创研究文章、信件、综述和药物临床试验研究。随着神经系统和CNS药物发现的新人类药物靶点的发现、鉴定、表征和验证的持续增长;这本杂志是所有参与药物发现和开发的药学科学家必不可少的阅读。
1871-5273SCIE/Scopus收录
3
3.2
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学3区
NEUROSCIENCES 神经科学
4区
PHARMACOLOGY & PHARMACY 药学
3区
N/A
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科:NEUROSCIENCES
SCIE
Q2
143/314
学科:PHARMACOLOGY & PHARMACY
SCIE
Q2
138/352
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科:NEUROSCIENCES
SCIE
Q3
210/314
学科:PHARMACOLOGY & PHARMACY
SCIE
Q3
189/353
78
129
-较难较慢,6-12周-医学-神经科学
3.3%
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
26.36%1.48%-
CiteScore:5.50
SJR:0.710
SNIP:0.603
学科类别分区排名百分位
大类:Pharmacology, Toxicology and Pharmaceutics
小类:Pharmacology
Q2
120 / 321
大类:Pharmacology, Toxicology and Pharmaceutics
小类:General Neuroscience
Q2
52 / 111

期刊高被引文献

A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527317666181119115532
Epigenetics in Neurodegenerative Diseases: The Role of Histone Deacetylases.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527317666181004155136
Ultramicronized Palmitoylethanolamide (um-PEA) as add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190227205359
Xuesaitong May Protect Against Ischemic Stroke by Modulating Microglial Phenotypes and Inhibiting Neuronal Cell Apoptosis via the STAT3 Signaling Pathway.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527317666181114140340
Neuro-psychiatric alterations in patients with diabetic foot syndrome.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666191002094406
New Drug Discovery from Medicinal Plants and Phytoconstituents for Depressive Disorders.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527317666181114141129
Omega-3 Fatty Acids as Druggable Therapeutics for Neurodegenerative Disorders.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666191114093749
Neuroprotective effects of cordycepin with anti-apoptosis mechanism based on mitochondrial pathway in rotenone-induced parkinsonism rat model.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190905152138
Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527317666180816095707
Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190131121827
Hydrolyzed Rutin Decreases Worsening of Anaplasia in Glioblastoma Relapse.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190314103104
The Effect of Vitamin D3 Supplementation on Serum BDNF, Dopamine and Serotonin in Children with Attention-Deficit/Hyperactivity Disorder.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190703103709
Motor Recovery after Chronic Spinal Cord Transection in Rats: A Proof-of-Concept Study Evaluating a Combined Strategy.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527317666181105101756
Effect of omega-3 supplementation on Expanded Disability Status Scale and Inflammatory Cytokines in multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190516083008
Generation and Characterization of a Functional Nanobody Against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527317666181114134518
Enhancement of hippocampal plasticity by physical exercise as a polypill for stress and depression: A review.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190308102804
Micronized Palmitoylethanolamide: A Post Hoc Analysis of a Controlled Study in Patients with Low Back Pain – Sciatica
来源期刊:CNS & Neurological Disorders Drug TargetsDOI:10.2174/1871527318666190703110036
Noncoding RNAs and Intracerebral Hemorrhage.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190204102604
Different Food Odors Control Brain Connectivity in Impulsive Children.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527317666181105105113
Co-ultraPEALut: Role in Preclinical and Clinical Delirium Manifestations.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190617162041
A Review for Lithium: Pharmacokinetics, Drug Design and Toxicity.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666191114095249
Carvedilol promotes retinal ganglion cell survival following optic nerve injury via ASK1-p38 MAPK pathway.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666191002095456
Causes and Consequences of MicroRNA Dysregulation Following Cerebral Ischemia-Reperfusion Injury.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190204104629
Grape seed proanthocyanidins protect N2a cells against ischemic injury via endoplasmic reticulum stress and mitochondrial associated pathways.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190212111650
Cannabidiol partially blocks the sleepiness in hypocretin-deficient rats. Preliminary data.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666191021143300
Jingshu Keli and Its Components Notoginsenoside R1and Ginsenoside Rb1 Alleviate the Symptoms of Cervical Myelopathy through Kir3.1 Mediated Mechanisms.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/0929866526666190911150514
Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190409103831
A Novel Botulinum Toxin TAT-EGFP-HCS Fusion Protein Capable of Specific Delivery Through the Blood-brain Barrier to the Central Nervous System.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527317666181011113215
Attenuating effect of Portulaca oleracea extract in chronic constriction injury induced neuropathic pain in rats: an evidence of anti-oxidative and anti-inflammatory properties.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190314110528
Childhood Hypertension and Effects on Cognitive Functions: Mechanisms and Future Perspectives.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666191017155442
Clinical characteristics and possible drug targets in autosomal dominant spinocerebellar ataxias.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190311155846
Computational Protein-Protein docking revealing the therapeutic potential of Kunitz-type Venom against hKv1.2 binding sites.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190319140204
Role of flavonoids in neurodegenerative disorders with special emphasis on tangeritin.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190916141934
Bibliometrics of CNS & Neurological Disorders - Drug Targets: An International Evolution Along Time.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666181227123924
Madecassic acid reduces fast transient potassium channels and promotes neurite elongation in hippocampal CA1 neurons.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666191111105508
Structurally Related Edaravone Analogues: Synthesis, Antiradical, Antioxidant, and Copper-Chelating Properties.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666191114092007
Autism Spectrum Disorders: The Association with Inherited Metabolic Disorders and Some Trace Elements. A Retrospective Study.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190430162724
Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and Its Neuroprotective Effects in Mice After Intracranial Hemorrhage.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527319666191220111126
Role of Vitamin D in Multiple Sclerosis and Other Neurodegenerative Processes: Bibliometric Analysis and Systematic Review.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190703102330
Somatostatin type 2 receptor antibody enhances mechanical hyperalgesia in the dorsal root ganglion neurons after sciatic nerve-pinch injury: Evidence of molecular and behavioral studies.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666191101094412
The associations between central nervous system diseases and haemostatic disorders.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190314101946
Central Histamine, The H3-Receptor and Obesity Therapy.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190703094846
Cytarabine and Ferric Carboxymaltose (Fe+3) Increase Oxidative Damage and Alter Serotonergic Metabolism in Brain.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666181128144343
Aberrant DNA methylation pattern may enhance susceptibility to migraine: A novel perspective.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666190809162631
Prion peptide 106-126 degradation potential of Serratiopetidase and Lumbrokinase - an in vitro and in silico perspective.
来源期刊:CNS & neurological disorders drug targetsDOI:10.2174/1871527318666191021150002

相关文章

2026年3月发布(新锐分区)
大类学科小类学科Top期刊综述期刊
医学3区
NEUROSCIENCES 神经科学
4区
PHARMACOLOGY & PHARMACY 药学
3区
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
NEUROSCIENCES 神经科学
4区
PHARMACOLOGY & PHARMACY 药学
4区
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学4区
NEUROSCIENCES 神经科学
4区
PHARMACOLOGY & PHARMACY 药学
4区